This can be mentally challenging when you are working hard to lose weight
Diaz-Castro B, Robel S, Mishra A
NHS waiting lists for these services are long, and many clinically eligible patients wait months or years
Given their glucose-lowering effects, GLP-1s have become standard of care for type 2 diabetes, supplanting other medication classes such as sulfonylureas.2 In 2023, GLP-1s represented 63% of diabetes spend, up from 38% in 2020.2 While diabetes GLP-1s will continue to account for a greater portion of spend compared to obesity, costs related to GLP-1s prescribed for obesity are expected to grow at a faster rate over the next 3 years
Here are some of the common issues and solutions people run into while traveling with semaglutide or tirzepatide
GHK-Cu is sold as research-use-only because it has not been evaluated by the FDA for human therapeutic use